Cargando…

Testing the efficacy of tocilizumab in patients with COVID-19 pneumonia

Detalles Bibliográficos
Autores principales:	Agirbasli, Mehmet, Tanrıkulu, Azra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098652/ https://www.ncbi.nlm.nih.gov/pubmed/33887951 http://dx.doi.org/10.2217/cer-2021-0050

Ejemplares similares

Tocilizumab is recommended for the treatment of severe COVID-19
por: Zhou, Yonggang, et al.
Publicado: (2020)

Tocilizumab in severe COVID-19: A promise fulfilled
por: Levi, Marcel
Publicado: (2022)

Why tocilizumab could be an effective treatment for severe COVID-19?
por: Fu, Binqing, et al.
Publicado: (2020)

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
por: Salama, Carlos, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Lipworth, Brian J, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Piano, Salvatore, et al.
Publicado: (2020)

Tocilizumab and PMX-DHP have efficacy for severe COVID-19 pneumonia
por: Shinomiya, Shohei, et al.
Publicado: (2021)

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
por: Rosas, Ivan O., et al.
Publicado: (2021)

Tocilizumab and steroid treatment in patients with COVID-19 pneumonia
por: Mikulska, Malgorzata, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19: A promising intervention affecting inflammation and coagulation
por: Levi, Marcel
Publicado: (2020)

The effects of antihypertensive medications on severity and outcomes of COVID19
por: Agirbasli, Mehmet
Publicado: (2022)

Thrombosis and fibrosis: mutually inclusive targets to combat in COVID-19
por: Agirbasli, Mehmet
Publicado: (2021)

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
por: Stone, John H., et al.
Publicado: (2020)

Efficacy and safety of tocilizumab in COVID-19 patients
por: Zheng, Kai-Lian, et al.
Publicado: (2020)

Prognostic significance of HDL-C on long-term mortality in patients with COVID-19 pneumonia in the Turkish population: A potential mechanism for population differences
por: Baycan, Ömer Faruk, et al.
Publicado: (2022)

Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients
por: Sarhan, Rania M., et al.
Publicado: (2022)

Tocilizumab for severe COVID-19 pneumonia – Authors' reply
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

563. Tocilizumab in the Treatment of Critical COVID-19 Pneumonia
por: Fisher, Matthew, et al.
Publicado: (2020)

Tocilizumab versus the Covid19 tempest: All’s well that ends well or much ado about nothing?
por: Lee, Todd C., et al.
Publicado: (2021)

Use of tocilizumab in COVID-19 pneumonia hospitalized patients. Cohort study
por: Anci, Cynthia, et al.
Publicado: (2023)

Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia
por: Chauvineau-Grenier, Angélique, et al.
Publicado: (2022)

Tocilizumab and COVID-19: Timing of Administration and Efficacy
por: Abidi, Emna, et al.
Publicado: (2022)

TOCIVID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol
por: Piccirillo, Maria Carmela, et al.
Publicado: (2020)

Matched cohort study on the efficacy of tocilizumab in patients with COVID-19
por: Rodríguez-Molinero, Alejandro, et al.
Publicado: (2021)

Efficacy of tocilizumab treatment in severely ill COVID-19 patients
por: Zhao, Jie, et al.
Publicado: (2020)

Tocilizumab improves survival in patients with persistent hypoxia in severe COVID-19 pneumonia
por: Gokhale, Yojana, et al.
Publicado: (2020)

PULMONARY ASPERGILLOSIS POST-TOCILIZUMAB TREATMENT IN A PATIENT WITH COVID-19 PNEUMONIA
por: GIDWANI, VIPUL, et al.
Publicado: (2022)

Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
por: Perrone, Francesco, et al.
Publicado: (2020)

Prevalence of Hospital-Acquired Pneumonia Among Patients With Severe to Critical COVID-19 Pneumonia Given Tocilizumab
por: Adre, Lorenzo Abednego B, et al.
Publicado: (2023)

Efficacy of Tocilizumab in COVID-19: Single-Center Experience
por: Kaya, Safak, et al.
Publicado: (2021)

Successful treatment of severe COVID-19 pneumonia and hyperinflammatory syndrome with tocilizumab
por: Gentile, Giorgio, et al.
Publicado: (2021)

342. Secondary Infections following Tocilizumab for Treatment of COVID-19 Pneumonia
por: Warner, Adam, et al.
Publicado: (2021)

Rapid radiological improvement of COVID-19 pneumonia after treatment with tocilizumab
por: Comel, Andrea Claudio, et al.
Publicado: (2020)

Effective treatment of severe acute pancreatitis and COVID-19 pneumonia with tocilizumab
por: Zielecki, Piotr, et al.
Publicado: (2020)

Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome
por: van Kraaij, Tom DA, et al.
Publicado: (2020)

High-flow nasal oxygen in severe COVID-19 pneumonia and tocilizumab
por: Mandal, M., et al.
Publicado: (2022)

Effects of Tocilizumab on Adults With COVID-19 Pneumonia: A Meta-Analysis
por: Chen, Chi-Chung, et al.
Publicado: (2022)

Real-Life Use of Tocilizumab in the Treatment of Severe COVID-19 Pneumonia
por: Alex, Ruth, et al.
Publicado: (2022)

A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical analysis plan
por: Chiodini, Paolo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7gqp3hi3083q8mrq8am515qqk4